Nephrogenic Systemic Fibrosis (NSF): An assessment of perception and practice of Nigerian MRI Radiographers.
Main Article Content
Abstract
Background: Nephrogenic Systemic Fibrosis (NSF) is a serious fibrotic disorder seen in patients with kidney impairment, triggered by gadolinium-based contrast agents (GBCAs) used in MRI. It manifests with skin thickening, joint contractures, and potential organ involvement, with no available cure. Linear GBCAs have higher associated risks, prompting global regulatory restrictions. As MRI utilization increases in Nigeria, the level of radiographers’ awareness and adherence to NSF prevention guidelines remains unclear. Assessing their training and clinical practices is essential for improving patient safety and aligning with international standards.
Objective: To assess the perception, knowledge, and clinical practices of MRI radiographers regarding NSF and GBCA safety.
Method: A descriptive cross-sectional study was conducted to evaluate knowledge, awareness, perception, and practices regarding NSF and GBCA safety among Nigerian MRI radiographers. Participants involved in patient screening and GBCA administration across multiple centers were surveyed using a structured, pre-tested questionnaire adapted from validated instruments. Data analysis employed descriptive and inferential statistics to assess understanding and compliance with NSF prevention protocols. Ethical approval and participant confidentiality were strictly maintained.
Results: Among 42 surveyed Nigerian MRI radiographers, 78.4% were aware of NSF, but only 37.8% demonstrated comprehensive knowledge of prevention guidelines. Overall knowledge was adequate; however, notable gaps existed concerning gadolinium contrast risks and renal function markers. Weight-based gadolinium dosing was commonly practiced. Renal screening protocols varied, being more consistently applied in private healthcare facilities. Radiographers’ experience and clinical role significantly influenced NSF knowledge, while the practice environment predicted adherence to safety measures.
Conclusion: MRI radiographers demonstrate general awareness of NSF, but gaps persist in guideline familiarity and standardized renal screening practices. Strengthening education, institutional protocols, and regulatory oversight may enhance patient safety and reduce NSF risk.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles in JRRS are published under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
How to Cite
References
1. Benzon H.T, Maus T.P, Kang H.R, Provenzano D.A, Bhatia A, Diehn F, et al. The use of contrast agents in interventional pain procedures: a multispecialty and multisociety practice advisory on nephrogenic systemic fibrosis, gadolinium deposition in the brain, encephalopathy after unintentional intrathecal gadolinium injection, and hypersensitivity reactions. Anesth Analg. 2021;133(2):535–552. https://doi.org/10.1213/ANE.0000000000005600
2. Igreja AC, Mesquita KD, Cowper SE, Costa IM. Nephrogenic systemic fibrosis: concepts and perspectives. An Bras Dermatol. 2012;87(4):597–607. https://doi.org/10.1590/S0365-05962012000400009
3. Woolen S.A, Shankar PR, Gagnier JJ, MacEachern MP, Singer L, Davenport MS. Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: a systematic review and meta-analysis. JAMA Intern Med. 2020;180(2):223–230. https://doi.org/10.1001/jamainternmed.2019.528
4. Attari H, Cao Y, Elmholdt TR, Zhao Y, Prince MR. A systematic review of 639 patients with biopsy-confirmed nephrogenic systemic fibrosis. Radiology. 2019;292(2):376–386. https://doi.org/10.1148/radiol.2019182744
5. Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, et al. Use of intravenous gadolinium-based contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation. Radiology. 2021;298(1):28–35. https://doi.org/10.1148/radiol.2020202909
6. Piersson AD, Gorleku PN. Nephrogenic systemic fibrosis: a survey of the use of gadolinium-based contrast agents in Ghana. Radiography. 2017;23(4): e108–e113. https://doi.org/10.1016/j.radi.2017.05.006
7. Madke B, Khopkar U. Nephrogenic systemic fibrosis. Indian Dermatol Online J. 2011;2(2):51–56. https://doi.org/10.4103/2229-5178.82995
8. Piersson AD, Gorleku PN. The use of gadolinium-based contrast agents in Ghana with a focus on residual intracranial gadolinium deposition. Radiography. 2018;24(3): e51–e56. https://doi.org/10.1016/j.radi.2018.04.004
9. Ezema CI, Erondu OF, Onyeso OK, Alumona CJ, Ijever AW, Amarachukwu CN, et al. Radiographers’ knowledge, attitude, and adherence to standard COVID-19 precautions and the policy implications: a national cross-sectional study in Nigeria. Ann Med. 2023;55(1):2210844. https://doi.org/10.1080/07853890.2023.2210844.
10. Najjar R. Clinical applications, safety profiles, and future developments of contrast agents in modern radiology: a comprehensive review. iRadiology. 2024;2(5):430–468.
11. PrinceMR, Arnoldus C, Frisoli JK. Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. J. Magn. Reson. Imaging. 1996; 1:162e6.
12. Prince, M. R., Zhang, H., Zou, Z., Staron, R. B., & Brill, P. W. (2011). Incidence of immediate gadolinium contrast media reactions. AJR. American Journal of Roentgenology, 196(2), W138–W143. https://doi.org/10.2214/AJR.10.48
13. Saab, G., & Abu-Alfa, A. (2008). Nephrogenic systemic fibrosis: Implications for nephrologists. European Journal of Radiology, 66(2), 175–179. https://doi.org/10.1016/j.ejrad.2008.01.028
14. Abdel-Kader, K., Patel, P. R., Kallen, A. J., Sinkowitz-Cochran, R. L., Bolton, W. K., & Unruh, M. L. (2010). Nephrogenic systemic fibrosis: A survey of nephrologists' perceptions and practices. Clinical Journal of the American Society of Nephrology, 5(5), 817–822. https://doi.org/10.2215/CJN.00140110
15. Schieda, N., Blaichman, J. I., & Hiremath, S. (2018). Gadolinium-based contrast agents in kidney disease: A comprehensive review and clinical practice guideline issued by the Canadian Association of Radiologists. Canadian Journal of Kidney Health and Disease, 5. https://doi.org/10.1177/2054358118778573
16. Quattrocchi, C. C., Rovira, À., & Mallio, C. (2024). ESR Essentials: Gadolinium-wise MRI—Practice recommendations by the European Society for Magnetic Resonance in Medicine and Biology. European Radiology. Advance online publication. https://doi.org/10.1007/s00330-024-11214-4.
17. American College of Radiology. (2023). ACR manual on contrast media. https://www.acr.org/Clinical-Resources/Contrast-Manual
18. Choi, J.W. and Won-Jin, M., 2019. Gadolinium deposition in the brain: current updates. Korean journal of radiology, 20(1), p.134.
19. Adin, M. E., & Yousem, D. (2021). Gadolinium retention in humans: Survey of radiologists and impact on daily practice. IUITFD-Journal of the Faculty of Medicine Istanbul University. https://doi.org/10.26650/IUITFD.2021.874672
20. Kanal, E., Borgstede, J. P., Barkovich, A. J., Bell, C., Bradley, W. G., Felmlee, J. P., Froelich, J. W., & Zinninger, M. D. (2002). American College of Radiology white paper on MR safety. AJR. American Journal of Roentgenology, 178(6), 1335–1347. https://doi.org/10.2214/ajr.178.6.1781335
21. Perez-Rodriguez, J., Lai, S., Ehst, B. D., Fine, D. M., & Bluemke, D. A. (2009). Nephrogenic systemic fibrosis: Incidence, associations, and effect of risk factor assessment—Report of 33 cases. Radiology, 250(2), 371–377. https://doi.org/10.1148/radiol.2502080498
22. Welker, K. M., Joyner, D., & Jordan, J. (2024). State of practice: ASNR statement on gadolinium-based contrast agent use in patients with chronic kidney disease. American Journal of Neuroradiology.https://doi.org/10.3174/ajnr.A8501